249 related articles for article (PubMed ID: 30552464)
21. NTP toxicity report of reproductive dose range-finding study of Genistein (CAS No. 446-72-0) administered in feed to Sprague-Dawley rats.
Delclos KB; Newbold R
Toxic Rep Ser; 2007 Nov; (79):1-C2. PubMed ID: 18685712
[TBL] [Abstract][Full Text] [Related]
22. Environmental effect assessment for sexual endocrine-disrupting chemicals: Fish testing strategy.
Knacker T; Boettcher M; Frische T; Rufli H; Stolzenberg HC; Teigeler M; Zok S; Braunbeck T; Schäfers C
Integr Environ Assess Manag; 2010 Oct; 6(4):653-62. PubMed ID: 20872646
[TBL] [Abstract][Full Text] [Related]
23. Enhanced prediction of internal concentrations of phenolic endocrine disrupting chemicals and their metabolites in fish by a physiologically based toxicokinetic incorporating metabolism (PBTK-MT) model.
Liu YH; Yao L; Huang Z; Zhang YY; Chen CE; Zhao JL; Ying GG
Environ Pollut; 2022 Dec; 314():120290. PubMed ID: 36180004
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of new alternative methods for the identification of estrogenic, androgenic and steroidogenic effects: a comparative in vitro/in silico study.
Najjar A; Wilm A; Meinhardt J; Mueller N; Boettcher M; Ebmeyer J; Schepky A; Lange D
Arch Toxicol; 2024 Jan; 98(1):251-266. PubMed ID: 37819454
[TBL] [Abstract][Full Text] [Related]
25. Extending an in vitro panel for estrogenicity testing: the added value of bioassays for measuring antiandrogenic activities and effects on steroidogenesis.
Wang S; Rijk JC; Besselink HT; Houtman R; Peijnenburg AA; Brouwer A; Rietjens IM; Bovee TF
Toxicol Sci; 2014 Sep; 141(1):78-89. PubMed ID: 24928889
[TBL] [Abstract][Full Text] [Related]
26. Dosimetric anchoring of in vivo and in vitro studies for perfluorooctanoate and perfluorooctanesulfonate.
Wambaugh JF; Setzer RW; Pitruzzello AM; Liu J; Reif DM; Kleinstreuer NC; Wang NC; Sipes N; Martin M; Das K; DeWitt JC; Strynar M; Judson R; Houck KA; Lau C
Toxicol Sci; 2013 Dec; 136(2):308-27. PubMed ID: 24046276
[TBL] [Abstract][Full Text] [Related]
27. Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol.
Klopčič I; Markovič T; Mlinarič-Raščan I; Sollner Dolenc M
Toxicol Lett; 2018 Sep; 294():95-104. PubMed ID: 29777833
[TBL] [Abstract][Full Text] [Related]
28. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop.
Bessems JG; Loizou G; Krishnan K; Clewell HJ; Bernasconi C; Bois F; Coecke S; Collnot EM; Diembeck W; Farcal LR; Geraets L; Gundert-Remy U; Kramer N; Küsters G; Leite SB; Pelkonen OR; Schröder K; Testai E; Wilk-Zasadna I; Zaldívar-Comenges JM
Regul Toxicol Pharmacol; 2014 Feb; 68(1):119-39. PubMed ID: 24287156
[TBL] [Abstract][Full Text] [Related]
29. Assessment of in vivo assays for endocrine disruption.
Clode SA
Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
[TBL] [Abstract][Full Text] [Related]
30. The Effects of Mono-(2-Ethylhexyl) Phthalate (MEHP) on Human Estrogen Receptor (hER) and Androgen Receptor (hAR) by YES/YAS In Vitro Assay.
Kim DH; Park CG; Kim SH; Kim YJ
Molecules; 2019 Apr; 24(8):. PubMed ID: 31010227
[TBL] [Abstract][Full Text] [Related]
31. Endocrine disrupters--testing strategies to assess human hazard.
Baker VA
Toxicol In Vitro; 2001; 15(4-5):413-9. PubMed ID: 11566572
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the rodent Hershberger bioassay: testing of coded chemicals and supplementary molecular-biological and biochemical investigations.
Freyberger A; Ellinger-Ziegelbauer H; Krötlinger F
Toxicology; 2007 Sep; 239(1-2):77-88. PubMed ID: 17688994
[TBL] [Abstract][Full Text] [Related]
33. An in vitro investigation of endocrine disrupting effects of the mycotoxin alternariol.
Frizzell C; Ndossi D; Kalayou S; Eriksen GS; Verhaegen S; Sørlie M; Elliott CT; Ropstad E; Connolly L
Toxicol Appl Pharmacol; 2013 Aug; 271(1):64-71. PubMed ID: 23665424
[TBL] [Abstract][Full Text] [Related]
34. The ability of the YAS and AR CALUX assays to detect the additive effects of anti-androgenic fungicide mixtures.
Seeger B; Klawonn F; Bekale BN; Steinberg P
Toxicol Lett; 2016 Jan; 241():193-9. PubMed ID: 26602169
[TBL] [Abstract][Full Text] [Related]
35. Multiple receptors shape the estrogen response pathway and are critical considerations for the future of in vitro-based risk assessment efforts.
Miller MM; McMullen PD; Andersen ME; Clewell RA
Crit Rev Toxicol; 2017 Aug; 47(7):564-580. PubMed ID: 28675057
[TBL] [Abstract][Full Text] [Related]
36. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the results of in vitro receptor binding assay to human estrogen receptor alpha and in vivo uterotrophic assay: comparative study with 65 selected chemicals.
Akahori Y; Nakai M; Yamasaki K; Takatsuki M; Shimohigashi Y; Ohtaki M
Toxicol In Vitro; 2008 Feb; 22(1):225-31. PubMed ID: 17904329
[TBL] [Abstract][Full Text] [Related]
38. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
39. Evaluation and Optimization of Pharmacokinetic Models for
Casey WM; Chang X; Allen DG; Ceger PC; Choksi NY; Hsieh JH; Wetmore BA; Ferguson SS; DeVito MJ; Sprankle CS; Kleinstreuer NC
Environ Health Perspect; 2018 Sep; 126(9):97001. PubMed ID: 30192161
[TBL] [Abstract][Full Text] [Related]
40. Towards an integrated in vitro strategy for estrogenicity testing.
Wang S; Aarts JM; de Haan LH; Argyriou D; Peijnenburg AA; Rietjens IM; Bovee TF
J Appl Toxicol; 2014 Sep; 34(9):1031-40. PubMed ID: 24114741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
